BDMD (Baird Medical Investment Holdings) Debt-to-EBITDA : 1.32 (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Baird Medical Investment Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Baird Medical Investment Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $14.17 Mil. Baird Medical Investment Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $1.35 Mil. Baird Medical Investment Holdings's annualized EBITDA for the quarter that ended in Jun. 2024 was $11.74 Mil. Baird Medical Investment Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 1.32.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Baird Medical Investment Holdings's Debt-to-EBITDA or its related term are showing as below:

BDMD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.21 Med: 0.46 Max: 0.95
Current: 0.95

During the past 3 years, the highest Debt-to-EBITDA Ratio of Baird Medical Investment Holdings was 0.95. The lowest was 0.21. And the median was 0.46.

BDMD's Debt-to-EBITDA is ranked better than
59.37% of 443 companies
in the Medical Devices & Instruments industry
Industry Median: 1.44 vs BDMD: 0.95

Baird Medical Investment Holdings Debt-to-EBITDA Historical Data

The historical data trend for Baird Medical Investment Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baird Medical Investment Holdings Debt-to-EBITDA Chart

Baird Medical Investment Holdings Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-EBITDA

0.21

0.46

0.82

Baird Medical Investment Holdings Semi-Annual Data
	Dec21	Dec22	Jun23	Dec23	Jun24
Debt-to-EBITDA	N/A	N/A	-	0.55	1.32

Competitive Comparison of Baird Medical Investment Holdings's Debt-to-EBITDA

For the Medical Devices subindustry, Baird Medical Investment Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Baird Medical Investment Holdings's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Baird Medical Investment Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Baird Medical Investment Holdings's Debt-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Baird Medical Investment Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Baird Medical Investment Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(9.488	+	2.026)	/	14.026
	=	0.82

Baird Medical Investment Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(14.166	+	1.351)	/	11.738
	=	1.32

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.

Baird Medical Investment Holdings (NAS:BDMD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Baird Medical Investment Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Baird Medical Investment Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Baird Medical Investment Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Baird Medical Investment Holdings Ltd (NAS:BDMD) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.15 Rongtong Street, Room 202, 2nd Floor, Baide Building, Building 11, Yuexiu, Guangzhou, CHN

Website

Baird Medical Investment Holdings Ltd is one of the microwave ablation medical device developers and providers in the PRC for minimally invasive treatment of tumors. Its proprietary medical devices are used for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast lumps. Microwave ablation is a minimally invasive treatment technique that denaturalizes and coagulates the protein of tumor cells with extreme heat generated by microwave energy. Microwave ablation treatments have been applied to benign and malignant tumors, and the company believes the products are safer, minimally invasive and easier to operate with faster recovery periods and lower complication rates for patients, as compared to traditional treatment methods.